NextGen Healthcare Inc. (NXGN) concluded trading on 09/14/23 at a closing price of $23.60, with 3.53 million shares of worth about $83.26 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 39.89% during that period and on Thursday the price remained unchanged. Currently the company’s common shares owned by public are about 66.42M shares, out of which, 44.25M shares are available for trading.
A deeper look into what the analysts at Wall Street are thinking about the price target of this stock provides us with the following: 9 analysts are covering the NXGN stock and their offered price forecasts bring an average price target of $23.46. Over the next 12 months, analysts forecasted that the stock’s price could jump as high as $24.00 and could fall to a lowest price of $21.90. The stock’s current price level is 0.97% above of average price target set by the analysts, while a rise to estimated low would result in loss of -7.76% for the stock. However, touching the estimated high of $24.00 would mean a gain of 1.67% for the stock.
According to filings with the U.S. Securities and Exchange Commission (SEC), insiders took part in trade of the company’s stock for 69 times over the past 12 months. They bought 714,444 shares in 30 of the transactions. In 39 selling transactions, insiders dumped 384,677 shares.
NextGen Healthcare Inc. (NASDAQ: NXGN) started trading at $23.62, above $0.02 from concluding price of the previous day. Stock saw a price change of -0.04% in past 5 days and over the past one month there was a price change of 40.90%. Year-to-date (YTD), NXGN shares are showing a performance of 25.67% which increased to 40.90% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $15.23 but also hit the highest price of $23.69 during that period. The average intraday trading volume for NextGen Healthcare Inc. shares is 906.15K. The stock is currently trading 21.39% above its 20-day simple moving average (SMA20), while that difference is up 33.27% for SMA50 and it goes to 33.84% higher than SMA200.
NextGen Healthcare Inc. (NASDAQ: NXGN) currently have 66.42M outstanding shares and institutions hold larger chunk of about 78.30% of that.
The stock has a current market capitalization of $1.58B and its 3Y-monthly beta is at 0.95. PE ratio of stock for trailing 12 months is 944.00, while it has posted earnings per share of $0.03 in the same period. Its PEG reads 134.86 and has Quick Ratio of 2.20 while making debt-to-equity ratio of 0.65. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for NXGN, volatility over the week remained 0.36% while standing at 2.32% over the month.
Analysts are in expectations that NextGen Healthcare Inc. (NXGN) stock would likely to be making an EPS of $0.25 in the current quarter, while forecast for next quarter EPS is $0.28 and it is $1.33 for next year. For the current quarter EPS, analysts have given the company a lowest target $0.24 which is $0.26 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of $0.25 in the same quarter a year ago. Stock’s fiscal year EPS is expected to drop by -265.90% while it is estimated to increase by 20.75% in next year. EPS is likely to grow at an annualized rate of 7.00% for next 5-years, compared to annual growth of -21.60% made by the stock over the past 5-years.
Analysts at 9 brokerage firms have issued recommendations for the NextGen Healthcare Inc. (NXGN)’s stock and average of those rates the stock at a “Moderate Buy” and assign it a score of 2.70. Out of those 9 Wall Street analysts, 1 recommended a “Buy” rating, while 8 were in favor recommending the stock as a “Hold” and 0 analyst recommended the stock as “Sell”.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Cantor Fitzgerald on August 28, 2023 offering an Overweight rating for the stock and assigned a target price of $21 to it.